You are here: Home » International » News » Others
Business Standard

Takeda-led Covid plasma treatment enters clinical trial with first patient

Takeda Pharmaceutical said an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays

Topics
Coronavirus | Coronavirus Vaccine

Reuters  |  TOKYO 

Photo: Reuters
Photo: Reuters

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays.

The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement.

Patients will be treated with Gilead Science Inc's Remdesivir alongside the plasma treatment, which will be provided by CSL Behring, Takeda and two other companies.

"We are hopeful that data from the clinical trial will be available before the end of the year," Bill Mezzanotte, chief medical officer of CSL Behring, said in the release.

The group had aimed to begin the clinical trial in July, but it was delayed pending regulatory approval. The National Institutes of Health in the U.S. is the trial's sponsor.

The alliance, which also includes Germany's Biotest AG and Octapharma Plasma, is working on a hyperimmune globulin therapy derived from blood plasma. It offers a standardised dose of antibodies and doesn't need to be limited to patients with matching blood types.

The World Health Organization has urged caution about plasma treatments for COVID-19 saying evidence they work is "low quality", even as the United States issued emergency authorisation for such therapies.

Testing and production of the treatments are also vulnerable to a scarcity of blood plasma from people who have recovered from COVID-19. In its release, the CoVIg Plasma Alliance urged such individuals to consider donating their plasma.

 

(Reporting by Rocky Swift; Editing by Kenneth Maxwell and Christopher Cushing)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 09 2020. 08:24 IST
RECOMMENDED FOR YOU
.